Drug firm Suven Life Sciences today received one product patent each from the US and South Korea for CNS molecule which could be used for treating various central nervous system disorders.
The product patents are valid through 2030, Suven Life Sciences said in a filing to the BSE.
"The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD)," it added.
Commenting on the development, Suven CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for Major Depressive Disorder (MDD) with high unmet medical need with huge market potential globally."
Also read: Here's why pharma sector will continue outperforming
With these new patents, Suven has a total of 19 granted patents from US and 15 granted patents from South Korea, the company said.
Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, it added.
Shares of Suven Life Sciences were trading 4.13 percent up at Rs 190.15 per scrip during afternoon trade on the BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
